MORE►
Panna Sharma
Presenting the First-Ever AI 75: Meet the Most Innovative Leaders in Artificial Intelligence in Dallas-Fort Worth
by Glenn Hunter | May 2, 2024
Dallas Innovates, the Dallas Regional Chamber, and Dallas AI have teamed up to launch the inaugural AI 75 list. The 2024 program honors the most significant people in AI in DFW in seven categories—the visionaries, creators, and influencers you need to know.
by Lance Murray |
Jan 19, 2024
Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.
Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.
In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG)....
MORE►
by Lance Murray |
May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE►
by Lance Murray |
Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....
MORE►
Lantern Pharma CEO Panna Sharma
Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO
by Bella Pinera | Aug 3, 2021
Panna Sharma has had a hand in four IPOs. The latest was finalized during the middle of COVID for his clinical stage biopharmaceutical oncology firm, Lantern Pharma. Now, he shares the phases to transforming a young private company into the next public success story.
MORE►
by Lance Murray |
Oct 7, 2019
This alum of Dallas startup accelerator Health Wildcatters is working with the National Cancer Institute's Developmental Therapeutics Branch on precision research and treatments.
MORE►
